Boston Scientific's Cyberattack Disrupts Guidance Despite Strong Demand
On September 8, 2026, Boston Scientific (NYSE:BSX) reported that a cyberattack on August 25 disrupted its manufacturing and shipping operations. As a result, the company is unlikely to meet its third-quarter or full-year 2026 guidance for net sales and adjusted earnings per share. Although production has resumed, the incident caused unmet demand due to order fulfillment issues rather than product quality concerns. The cyberattack added complications to an already challenging environment in Boston Scientific's electrophysiology segment, which had seen growth projections revised downward earlier this year. The disruption exposed operational vulnerabilities and led investors to reassess near-term earnings expectations. Additionally, the incident could impact customer retention as competitors like Medtronic or Johnson & Johnson may gain procedures during shipping delays. Despite these challenges, Boston Scientific's core business remains intact, with its Farapulse system maintaining a strong position in the U.S. atrial-fibrillation market. The selloff presents an opportunity for long-term investors who believe in the company’s potential recovery and growth in pulsed-field ablation technology.
Topics: cybersecurity guidance revision medical devices operational disruption